238 related articles for article (PubMed ID: 32780261)
1. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
[TBL] [Abstract][Full Text] [Related]
2. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
[TBL] [Abstract][Full Text] [Related]
3. Trametinib for progressive pediatric low-grade gliomas.
Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
5. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
[TBL] [Abstract][Full Text] [Related]
6. Trametinib-based Treatment of Pediatric CNS Tumors: A Single Institutional Experience.
Paul MR; Pehlivan KC; Milburn M; Yeh-Nayre L; Elster J; Crawford JR
J Pediatr Hematol Oncol; 2020 Nov; 42(8):e730-e737. PubMed ID: 32398601
[TBL] [Abstract][Full Text] [Related]
7. Neuropsychological impact of trametinib in pediatric low-grade glioma: A case series.
Peterson RK; McKeown T; Tabori U; Bartels U; Bouffet E; Janzen L
Pediatr Blood Cancer; 2020 Dec; 67(12):e28690. PubMed ID: 32930446
[TBL] [Abstract][Full Text] [Related]
8. Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma.
Ronsley R; Hounjet CD; Cheng S; Rassekh SR; Duncan WJ; Dunham C; Gardiner J; Ghag A; Ludemann JP; Wensley D; Rehmus W; Sargent MA; Hukin J
Cancer Med; 2021 Jun; 10(11):3556-3564. PubMed ID: 33939292
[TBL] [Abstract][Full Text] [Related]
9. Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma.
Leclair NK; Lambert W; Roche K; Gillan E; Gell JJ; Lau CC; Wrubel G; Knopf J; Amin S; Anderson M; Martin JE; Bookland MJ; Hersh DS
Neurosurg Focus; 2022 Dec; 53(6):E15. PubMed ID: 36455272
[TBL] [Abstract][Full Text] [Related]
10. Use of Trametinib in Children and Young Adults With Progressive Low-grade Glioma and Glioneuronal Tumors.
Hanzlik E; Archambault B; El-Dairi M; Schroeder K; Patel MP; Lipp ES; Peters KB; Ashley DM; Landi D
J Pediatr Hematol Oncol; 2023 May; 45(4):e464-e470. PubMed ID: 36730221
[TBL] [Abstract][Full Text] [Related]
11. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor.
Lazow MA; Lawson SA; Salloum R; Hummel TR; Pillay Smiley N; DeWire-Schottmiller MD; Fouladi M; de Blank P
J Pediatr Hematol Oncol; 2021 May; 43(4):e550-e553. PubMed ID: 32520842
[TBL] [Abstract][Full Text] [Related]
12. Impact of trametinib on the neuropsychological profile of NF1 patients.
Lalancette E; Cantin É; Routhier MÈ; Mailloux C; Bertrand MC; Kiaei DS; Larouche V; Tabori U; Hawkins C; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; McKeown T; Ospina LH; Vairy S; Ramaswamy V; Coltin H; Sultan S; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Caru M; Dehaes M; Jabado N; Perreault S; Lippé S
J Neurooncol; 2024 May; 167(3):447-454. PubMed ID: 38443693
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.
Cacciotti C; Choi J; Alexandrescu S; Zimmerman MA; Cooney TM; Chordas C; Clymer J; Chi S; Yeo KK
J Neurooncol; 2020 Aug; 149(1):113-122. PubMed ID: 32627129
[TBL] [Abstract][Full Text] [Related]
14. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
[TBL] [Abstract][Full Text] [Related]
15. Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.
Li F; Bondra KM; Ghilu S; Studebaker A; Liu Q; Michalek JE; Kogiso M; Li XN; Kalapurakal JA; James CD; Burma S; Kurmasheva RT; Houghton PJ
Clin Cancer Res; 2022 Sep; 28(17):3836-3849. PubMed ID: 35797217
[TBL] [Abstract][Full Text] [Related]
16. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY
J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
18. Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment.
Tsai JW; Choi JJ; Ouaalam H; Murillo EA; Yeo KK; Vogelzang J; Sousa C; Woods JK; Ligon KL; Warfield SK; Bandopadhayay P; Cooney TM
Neurooncol Adv; 2023; 5(1):vdac182. PubMed ID: 36926246
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of combination carboplatin and vinblastine for pediatric low-grade glioma.
Nellan A; Wright E; Campbell K; Davies KD; Donson AM; Amani V; Judd A; Hemenway MS; Raybin J; Foreman NK; Rush S; Dorris K
J Neurooncol; 2020 Jul; 148(3):569-575. PubMed ID: 32506370
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapy Win in BRAF-Mutant Gliomas.
Cancer Discov; 2023 Nov; 13(11):2299-2300. PubMed ID: 37732735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
